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Interleukin-l0 Is a Proliferation Factor But Not a Differentiation Factor for Human Myeloma Cells
By
5,000 pg/celV24
These data suggest that one of the abnormalities in MM is a lack of differentiation of malignant plasma cells into mature plasma cells. Two cytokines have been shown to induce the generation of normal mature plasma cells secreting high rate of Ig. Interleukin-6 (IL-6) is the main cytokine responsible for the differentiation of proliferating normal early plasmablastic cells into mature plasma c e k 9 It is also the only presentlyidentified proliferation factor of normal early plasmablastic have shown that IL-6 is a major growth factor for malignant plasma cells in humans or in But IL-6 cannot induce further maturation of malignant plasma cells cells as it does for normal plasmablastic cell^.^.^ IL-10 has recently been shown to be the most potent inducer of Ig secretion in various systems of B-cell activation in vitro." This cytokine displays pleiotropic effects on various cell lineages23 and is produced by numerous cell types and particularly by n~r m a l '~.~~ and malignant B In the CD40 system:' IL-10 induces transient proliferation of activated B cells followed by a complete differentiation of these cells into mature plasma cells.22 In the EL-4 T-celldependent culture system, it is the main cytokine responsible for the terminal differentiation of plasma cells." For these reasons, we investigated its activity on malignant plasma cells involved in human MM. We report here that, similarly to IL-6, IL-10 is unable to induce further differentiation of malignant plasma cells. On the contrary, this cytokine is a potent, IL-6-unrelated myeloma cell growth factor. and one Bence-Jones k MM. Twelve of 15 patients had detectable proliferating myeloma cells in vivo (greater than 0.5%). IL-10 was searched for in the sera of 89 patients with MM and 20 patients with PCL. The characteristics of this patient population were previously de~cribed.'~ BM samples were also obtained from three healthy individuals after informed consent was given.
Cultures of freshly explanted tumor samples. Mononuclear cells (MCs) from tumor samples were separated on Ficoll Hypaque (Pharmacia, Uppsala, Sweden). For patient no.
1 1, a virtually pure population of myeloma cells (greater than 98%) was obtained by removing adherent cells and T cells using anti-CD3 monoclonal antibodies (MoAbs) and magnetic beads. MCs were cultured at lo6 cells/mL in RPM11640 supplemented with 2 mmoVL of L-glutamine and 5% fetal calf serum. In some culture groups, various recombinant (r) IL-IO concentrations (2, 10, 50, or 250 ng/mL) and an anti-L6 MoAb (B-E8 MoAb, 10 mg/mL) were added at the beginning of the culture. 10 pg/mL of B-E8 MoAb could neutralize 50 ng/mL of IL-6 (B. Klein, unpublished results, September 1990). Control cultures were performed with a mouse-purified IgGl MoAb recognizing no human antigens. After 5 days of culturing, cells were counted and harvested. Culture supernatants were filtered and stored at -20°C until use. The percentage of myeloma cells in S-phase (labeling index [LI]) was evaluated using a double immunofluorescence procedure." Plasma cells were first labeled using anti-K or anti-X Ig light-chain antibodies (Kallestadt, Austin, TX), then with an anti/Sphase MoAb (Immunotech, Marseilles, France). At least 5,000 myeloma cells were examined to determine these percentages. This ensured that the lowest L1 could be determined with a 30% precision 2522 and a P value less than .05. In some culture groups, tumor samples were cultured with no cytokine or with 50 ng/mL of rIL-l0 to assay the production of endogenous IL-6 and IL-10.
Measurement of IL-6, IL-IO, and Ig production. IL-6 activity was measured using the B9 hybridoma assay as reported elsewhere." The concentration of IL-10 in culture supernatants and patients' plasma was evaluated using a sensitive enzyme-linked immunosorbent assay (ELISA; Human myeloma cell lines (HMCLs). Four HMCLs were studied: XG-l, XG-2, XG-4, and XG-6.
All had cytoplasmic Ig, expressed plasma-cell antigens (Ag) (CD38 and syndecan-l) and lacked the usual B-cell Ag (CD19 and CD20). They did not produce IL-6, but their growth was completely dependent on addition of exogenous IL-6. Their detailed characteristics have been reported elsewhere.'' To investigate their responsiveness to various cytokines, XG cells were washed once with culture medium, incubated for 5 hours at 37°C in culture medium alone and washed again twice. The cells were then cultured at various concentrations in 96-well flatbottomed microplates for 5 days with either culture medium alone or graded concentrations of various cytokines. Tritiated thymidine (0.5 pCi of 25 CI/mmoliL; CEA, Saclay, France) was added for the last 8 hours of culture, and tritiated-thymidine incorporation was determined as reported e l s e~h e r e .~~ Polymerase chain reaction (PCR) analysis. cDNA was synthesized from 1 mg total RNA. Thirty-five PCR cycles (60 seconds at 9 4 T , 45 seconds at 6 0 T , and 60 seconds at 72°C) followed by a 3-minute extension at 72°C were performed using primers corresponding to nucleotides 316-339 and 638-664 of the L 1 0 sequence. Fifteen milliliters of each 25-mL PCR reaction were electrophoresed on I S% agarose gel in TRIS-acetateEDTA (TAE) buffer and transferred onto Hybond N filters (Amersham, Les Ulis, France). Filters were hybridized with an IL-l0 cDNA probe labeled with '*P(deoxycytidine triphosphate) by a random priming method (Boehringer Mannheim, Meylan, France) and exposed to Kodak XAR5 films (Eastman-Kodak, Rochester, NY) at -70°C for 2 hours.
Reagents. Recombinant IL-6 was provided by D. Stinchcomb (Synergen, Boulder, CO); rIL-l0 by J. Banchereau (Schering Plough, Dardilly, France) and J. Wijdenes; and anti-IL-6 (B-E8) and anti-IL-6R (B-R6) neutralizing MoAbs by J. Wijdenes. Antihuman CD3 MoAb, magnetic beads coupled to antimurine IgG antibodies, and control mouse-purified IgGl MoAb were purchased from Immunotech (Marseille, France).
Statistical analyses. For a given patient, the percentages of myeloma cells in S-phase were compared using the chi-square test. When the whole population of myeloma patients was considered, these percentages were compared using the nonparametric Wilcoxon test for pairs.
RESULTS
[L-l0 supports the growth of IL-&dependent HMCLs but does not induce them to differentiate. We investigated the effect of rIL-10 on the growth of 4 HMCLs (XG-I, XG-2, XG-4, and XG-6) whose proliferation was completely dependent on addition of exogenous IL-6.?' rIL-10 had no effect on XG-4 and XG-6, but significantly stimulated XG-1 and XG-2 cultures without rIL-6 (Fig 1) . Half-maximal proliferation was obtained with about 10 ng/mL of rIL-10. No synergistic effect could be found between rIL-6 and rIL-10 (results not shown), and anti-IL-6 or anti-IL-6R MoAb did not abrogate the stimulatory effect of rIL-l0 (Fig 2) . XG-1 and XG-2 cells produced no detectable IL-I0 (less than 1 pg/mL) and failed to express IL-IO mRNA in PCR assays (results not shown). XG-1 cells were further cultured without exogenous cytokines, or with rIL-6, or with 50 ng/ mL of rIL-10. Without addition of exogenous cytokine, XG-1 cells died within 9 days (Fig 3A) . With rIL-6, tremendous growth occurred. With rIL-10, cells began to grow after the first 6 days of culture (Fig 3A) , and an rIL-10-dependent subclone, termed XG-1-10, was subsequently obtained. rIL-10 efficiently supported the long-term growth of XG-1-10 cells, but rIL-6 remained the most efficient cytokine (Fig  3B) . XG-1-10 cells were IO-fold more sensitive to IL-IO than XG-1 cells (half-maximal proliferation, 1 ng/mL) (Fig Fig 5) .
Cytologic studies indicated that XG-1 cells were immature plasmablastic cells (greater than 95%) and produced low amount of Ig (3 ng/106 cells/24 hours). rIL-10 was unable to increase the rate of Ig production of XG-1 cells or to induce cytologic differentiation (results not shown). Accordingly, XG-1-10 were also immature plasmablastic cells (greater than 95%) and their Ig production was low, similar to that of XG-1 cells.
Such IL-lO/dependent subclones were repeatedly obtained by culturing XG-1 cells with rIL-l0 alone. IL-10-dependent subclones were also obtained by culturing XG-2 cells with rIL-10 alone (Fig 6) .
IL-l0 stimulates the proliferation of freshly-explanted myeloma cells, but does not induce them to dtyerentiate. Three of 15 patients had no detectable proliferating myeloma cells in vivo (L1 less than 0.5%). According to our previous st~dies,~' these 3 patients showed no spontaneous proliferation of plasmablastic cells in vitro (Table l) , and rIL-10, but not rIL-6, was able to induce detectable proliferation in 2 of these 3 patients. Proliferating myeloma cells were detected in the other 12 patients in vivo (L1 greater than 0.5%). A spontaneous in vitro proliferation of malignant plasmablastic cells was detected in 10 of these 12 patients (median LI, 1.3%, range, 0% to 2.7%). According to our previous experience, this spontaneous proliferation was mediated by the endogenous IL-6 largely produced in these cultures (Table  2) because it was dramatically inhibited by an anti-IL-6 MoAb (median LI, 0.05%; P = .Owl; Table 1 ). Recombinant IL-6 (1 ng/mL) only slightly increased by 17% the spontaneous myeloma cell proliferation. Addition of rIL-10 increased it by 217% (median LI, 2.8; P = .0005). This stimulatory effect was only partly inhibited by anti-IL-6 antibodies (median LI, 1.5%; P = .0005) indicating that rIL-10 and endogenous L 6 have additive stimulatory effects on myeloma cell proliferation (Table 1) .
For the first two patients, BM cells were cultured with various concentrations of rIL-l0 (2 to 250 ng/mL). Optimal stimulation was found with 10 to 50 ng/mL and this last concentration was used in subsequent experiments. For each patient, all plasma cells detected in day 5 cultures were monoclonal, producing the same isotype of light-chain Ig as that of the patient's monoclonal component. Pure plasma cells were available for patient no. 11 (greater than 98%). Similarly, rIL-10 was able to stimulate the proliferation of this pure population of myeloma cells (Table 1 ). Figure 7 shows the means of myeloma cell counts on day 5 in the different culture groups of the 12 patients with active disease that were significantly increased with rIL-IO (200%; P = .015). Rates of monoclonal Ig production by myeloma cells were evaluated in the rIL-IO-andor anti-lL-6 MoAbsupplemented culture groups from I O patients. These rates were unaffected by addition of rIL-IO ( P = .69): 2.77 pg/ myeloma ceIV24 hours (range, 0.32 to 12.5) in the anti-IL-6 MoAb-supplemented culture group versus 2.9 pg/myeloma ceIV24 hours (range, 0.17 to 15) in the rIL-IO-and anti-IL-6 MoAb-supplemented culture group.
For six patients with active disease, including patients nos. 7 and 1 I with extramedullary proliferation, attempts were made to obtain myeloma cell lines by repeated addition of fresh culture medium and rIL-IO, but myeloma cells progressively died within 1 month. Cytokine production in the presence of rlL-IO. As indicated in Table 2 , mean IL-6 concentrations in 5-day culture supernatants for the 7 patients with active disease were decreased by 53% in rIL-IO-supplemented culture groups as compared with control groups (881 v 1,893 pg/mL, P = .009). A low concentration of IL-I O was detected in 5 of the 7 culture supernatants of patients with active disease ( Table  2) . Serum IL-IO in patients with MM. When a very sensitive ELSA (1 pg/mL) was used, IL-IO was detected in only 3 of 89 patients with MM and medullary involvement alone (Fig 8) . On the contrary, IL-IO was detected in the sera of 12 of 20 patients with plasma cell leukemia (Fig 8) . Serum IL-l0 was undetectable in 150 sera of age-related healthy individuals (J. Wijdenes, unpublished results, January 1994).
Days of Culture

DISCUSSION
The present study shows that IL-IO is a growth factor for malignant plamablastic cell lines and that IL-IO-dependent HMCLs can be obtained. This is the first evidence that IL-I O might be a growth factor for malignant B cells. These HMCLs were obtained from MM patients with extramedullary proliferation using IL-6 and GM-CSF.3' Their growth became progressively dependent on addition of exogenous IL-6 alone and remained IL-6-dependent for several years. Interestingly, the growth-promoting activity of rIL-IO was independent of IL-6 because it was unaffected by anti-rlL-6 or anti-IL-6R MoAb. These HMCL had a plasmablastic cytology and their rate of Ig production was very low. rlL-10 did not induce differentiation of these immature myeloma cells and did not increase their rate of Ig production.
We also show that IL-IO is a growth factor for freshly use only.
For 
Tumor samples from patients with MM were incubated for 5 days with no cytokine (control), with 1 ng/mL of rlL-6, 50 nglmL of rlL-10, 10 pgl mL of the B-E8 anti-IL-6 MoAb, or 50 nglml of rlL-l0 and 10 pg/mL of B-E8 anti-IL-6 MoAb. Results are the percentages of myeloma cells in S-phase. Statistical comparisons were performed using the nonparametric Wilcoxon test for pairs. IL-6 (1 ng/mL) and IL-10 (50 ng/mL), P = ,0005; anti-IL-6 (10 pglmLI and IL-10 + anti-IL-6, P = ,001; control, 1L-6 (1 nglmL), IL-10 (50 nglmL), P = .0005; control, IL-6 (1 nghL), IL-10 (50 nglmL), anti-IL-6 (10 pg/mL), P = ,0001. Tumor samples from patients with MM were cultured at 1 x loe cells/mL for 5 days with or without 50 ng/mL of rlL-10, and culture supernatants were then harvested. IL-6 activity was measured by the B9 bioassay and IL-10 by an ELISA. IL-6 activities in the IL-10 group and control group were compared using a t-test for pairs. use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From neous proliferation of myeloma cells occurring in short-term cultures of tumor samples. However, the almost complete inhibition of this spontaneous proliferation of myeloma cells by an anti-IL-6 MoAb, in agreement with previous stud-IO and emphasizes that of IL-6. This situation may be attributable to the low concentrations of IL-IO detected in the culture supernatants of tumor samples (about I 00-fold lower than the IL-l0 concentrations active on fresh myeloma cells). Conversely, IL-6 concentations in these culture supernatants were about IO-fold greater than those active on myeloma cells. Thus, the bioactive concentrations of IL-6 in culture supernatants of tumor samples are 1,000-fold higher than those of IL-IO.
It is naturally very difficult to evaluate whether IL-IO plays a role in the emergence of the myeloma cell clone in vivo. In a previous study, using an ELISA that was not very sensitive, we found high levels of circulating IL-IO only in a subset of patients with solitary plasmacytoma and long survival. No circulating IL-l0 was detected in patients with overt MM.3h These data were confirmed in the current study using an ELISA that was 100-fold more sensitive ( 1 pg/mL). Indeed no IL-l0 was detected in the sera of 86 of 89 patients with MM with medullary involvement alone, and the three positive patients had no remarkable clinical features. 1L-IO mRNA was detected by PCR, but not by Northern blot analyses in BM cells of MM patients as well as of healthy individuals. Taken together, these data do not clearly indicate whether IL-IO is involved or not in the emergence of the tumor clone in patients with medullary involvement alone. However, this cytokine may be involved in the late phases of MM in vivo because IL-IO was detected in the sera of 60% of the patients with plasma cell leukemia. unrelated to 1L-6 because all cultures were performed with a potent neutralizing anti-IL-6 MoAb neutralizing up to 50 ng of IL-6. Moreover, in accordance with its previouslyreported antiinflammatory properties," rlL-l0 in fact reduced (50%) endogenous IL-6 production in these shortterm BM cultures. For the six patients studied, including one with plasma-cell leukemia and one with ascite, we were unable to obtain myeloma cell lines with IL-IO alone. In our experience, no myeloma cell lines could be obtained with IL-6 alone. This obtaining requires an initial stimulation with GM-CSF or IL-3 together with IL-6." Thus, an additional cytokine or activation signal may be critical to obtain IL-IO-dependent myeloma cell lines from freshly explanted tumor samples.
In agreement with numerous previous reports,"' the rates of Ig secretion by freshly-explanted myeloma cells in this study were very low (0.15 to 12.5 pg/ce11/24 hours) compared with those reported for normal plasma cells (100 to 5,000 pg/ce11/24 hours)."." This study shows that IL-l0 was unable to increase Ig secretion by freshly-explanted myeloma cells as well as by HMCLs. Previous studies showed that IL-6 also failed to increase Ig secretion by myeloma cells.5.h As these two cytokines are the major inducer of high Ig rate secreting plasma cells in healthy individuals, these results suggest that myeloma cells are no more able to differentiate into mature plasma cells and are frozen in a stage of immature plasma cells. Abnormalities in the transduction signals mediated by these cytokines might explain this blockage of the differentiation of myeloma cells. For a G-CSF transducer, which is very homologous to gp130 IL-6 transducer, a proliferation activity was associated with activation of MAP kinases unlike a differentiation a~tivity.'~ As several groups have shown that IL-6 is a major growth factor for human myeloma cells,'h''x it is debatable whether IL-IO plays a physiologic role as a myeloma growth factor. No efficient neutralizing anti-IL-10 antibodies were available for our study, so that it could not be investigated directly whether endogenous IL-IO partly contributed to the sponta-
